Abstract | OBJECTIVES: BACKGROUND: METHODS: RESULTS: The incidence of atrial fibrillation/flutter was 53 to 984 (5.4%) in the placebo group and 22 to 975 (2.3%) in the carvedilol group, giving a carvedilol/placebo hazard ratio (HR) of 0.41 (95% confidence interval [CI] 0.25 to 0.68; p = 0.0003). The corresponding rates of ventricular tachycardia/flutter/fibrillation were 38 to 984 (3.9%) and 9 to 975 (0.9%) (HR 0.24, 95% CI 0.11 to 0.49; p < 0.0001). CONCLUSIONS:
Carvedilol has a powerful antiarrhythmic effect after AMI, even in patients already treated with an ACE inhibitor. Carvedilol suppresses atrial as well as ventricular arrhythmias in these patients.
|
Authors | John McMurray, Lars Køber, Michele Robertson, Henry Dargie, Wilson Colucci, Jose Lopez-Sendon, Willem Remme, D Norman Sharpe, Ian Ford |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 45
Issue 4
Pg. 525-30
(Feb 15 2005)
ISSN: 0735-1097 [Print] United States |
PMID | 15708698
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Carbazoles
- Propanolamines
- Carvedilol
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Arrhythmias, Cardiac
(etiology, prevention & control)
- Carbazoles
(therapeutic use)
- Carvedilol
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(complications)
- Propanolamines
(therapeutic use)
- Prospective Studies
|